All three HDAC inhibitors exhibited common ADRs, including Thrombocytopenia, Decreased Neutrophil Count, Decreased Platelet Count, Investigations, General Disorders and Administration Site Conditions, as well as Gastrointestinal Disorders. The gene discussed is HDAC9; the disease is Thrombocytopenia.